Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: A multicentre, randomised, double blind study

Gut

Volumn 52, Issue 6, 2003, Pages 820-826

  Hawkey, C J ^a   Laine, L ^b   Simon, T ^c   Quan, H ^c   Shingo, S ^c   Evans, J ^c  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DUODENUM ULCER; ENDOSCOPY; FEMALE; GASTRODUODENAL ULCER; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INCIDENCE; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STOMACH EROSION; STOMACH ULCER;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; LIFE TABLES; MALE; MIDDLE AGED; NAPROXEN; PEPTIC ULCER; RISK FACTORS; SULFONES;

EID: 0037562163     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.6.820     Document Type: Article

References (34)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal taxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
2. Loebl DH, Craig R, Culic D, et al. Gastrointestinal blood loss: effect of aspirin, fenoprofen, and acetaminophen in rheumatoid arthritis as determined by sequential gastroscopy and radioactive fecal markers. JAMA 1977;237:976-81.
3. Hawkey CJ, Jackson L, Harper SE, et al. The gastrointestinal safely profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment Pharmacol Ther 2001;15:1-9.
4. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43:978-87.
5. Day R, Morrison B, Luza M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000;160:1781-7.
6. Ehrich EW, De Dallob A, Lepeliere I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-47.
7. Merck & Co., Inc. Vioxx (Rofecoxib Tablets and Oral Suspension). Physicians Desk Reference. Montvale, NJ: Medical Economics Company, 2000;1912-15.
8. Morrison BW, Daniels SE, Kotey P, et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999;94:504-8.
9. Wright N, Garlick N, Calder N, et al. Evidence that the COX-2 specific inhibitor rofecoxib at 50 mg spares gastric mucosal prostaglandin synthesis in humans. Gut 1999;45(suppl V):A25.
10. Cryer B, Gottesdiener K, Gertz B, et al. In vivo effects of rofecoxib, a new cyclooxygenase (COX)-2 inhibitor, on gastric mucosal prostaglandin (PG) and serum thromboxane B2 (TXB2) synthesis in healthy humans (abstract). Am J Gastroenterol 1999;91:1907.
11. Bjarnason I, Zanelli G, Smith T, et al. The pathogenesis and consequence of nonsteroidal anti-inflammatory drug induced small intestinal inflammation in man. Scand J Rheumatol 1987;64(suppl 69):55-62.
12. Ridolfo, AS, Crobtree, RE, Johnson, DW, et al. Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal anti-inflammatory agents. J Rheumatol 1980;7(suppl 6):36-47.
13. Hunt R, Bowen B, Mortensen E, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000;109:201-6.
14. Sigthorsson G, Crane R, Simon T, et al. Cox-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects. A double-blind, crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527-32.
15. Lanza FL, Rack MF, Simon TJ, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999;13:761-7.
16. Hawkey C, Laine L, Simon T, et al. A randomized, double-blinded comparison of the effect of refecoxib (a drug specifically inhibiting COX-2), ibuprofen, or placebo on the gastroduodenal mucosa of osteoarthritis patients. Arthritis Rheum 2000;43:370-7.
17. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
18. Langman M, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAID's. JAMA 1999;282:1929-33.
19. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18(suppl 28):6-10.
20. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 1994;91:12013-7.
21. Vane J. Towards a better aspirin. Nature 1994;367:215-16.
22. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 1994;91:3228-32.
23. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;115:787-96.
24. Bombardier C, Laine L, Reicin A, et al for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
25. Breslow EN, Crowley J. A large sample study of the life table and product limit estimates under random censorship. Ann Stat 1974;2:437-53.
26. Graham DY. High-dose famotidine for prevention of NSAID ulcers. Gastroenterology 1997;112:2143-5.
27. Taha AS, Sturrock RD, Russell RI. Mucosal erosions in long term non-steroidal anti- inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori. Gut 1995;36:334-6.
28. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:257-62.
29. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
30. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-9.
31. Hawkey CJ, Laine L, Harper SE, et al for the Rofecoxib Osteoarthritis Endoscopy Mutinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001;15:1593-601.
32. Saag K, van-der-Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000;9:1124-34.
33. Truitt KE, Lee M, DeTora LM, et al. Results of a pivotal (phase III) placebo and active comparator controlled efficacy trial of rofecoxib 12.5 and 25 mg in adult patients with rheumatoid arthritis (RA). Arthritis Rheum 2001;44(9 suppl):S369.
34. Truitt KE, Guesens PP, DeTora LM, et al. Results of a pivotal (phase III) placebo and active comparator controlled efficacy trial of rofecoxib 25 and 50 mg in adult patients with rheumatoid arthritis (RA). Ann Rheum Dis 2001;60(suppl 1):161